Quick Briefing on Pfizer

Shares of Health Care sector company Pfizer moved -0.5% today, and are now trading at a price of $28.64. The large-cap stock's daily volume was 33,340,663 compared to its average volume of 31,466,542. The S&P 500 index returned a 0.0% performance.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company is based in New York and has 83,000 full time employees. Its market capitalization is $161,713,192,960. Pfizer currently offers its equity investors a dividend that yields 5.7% per year.

21 analysts are following Pfizer and have set target prices ranging from $29.7 to $69.61 per share. On average, they have given the company a rating of buy. At today's prices, PFE is trading -22.84% away from its average analyst target price of $37.12 per share.

Over the last year, PFE shares have gone down by -44.8%, which represents a difference of -60.2% when compared to the S&P 500. The stock's 52 week high is $54.93 per share and its 52 week low is $28.3. With average free cash flows of $18.61 Billion that have been growing at an average rate of 13.0% over the last 6 years, Pfizer declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cash Flow ($ k) YoY Growth (%)
2023 22,730,000 3,864,000 18,866,000 -27.52
2022 29,267,000 3,236,000 26,031,000 -13.84
2021 32,922,000 2,711,000 30,211,000 148.1
2020 14,403,000 2,226,000 12,177,000 15.51
2019 12,588,000 2,046,000 10,542,000 -23.85
2018 15,827,000 1,984,000 13,843,000
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.